Wockhardt Limited Investor Presentation By Dr. Murtaza Khorakiwala Managing Director Q1FY16
Safe Harbor Statement • Except for historical information contained herein, statements in this communication, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “August”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue” and similar expressions or variations of such expressions August constitute “forward looking statements”. These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. Wockhardt Limited does not undertake any obligation to update forward looking statements to reflect events or circumstances after the date thereof. Investor Presentation August 2015 2
Introduction to Wockhardt Key Business Dynamics
Wockhardt Today UK, Ireland, France, Switz. Direct Operations USA in India , USA Mexico and Europe India Multi Ethnic workforce from 21 different Nationalities Wockhardt Direct ROW operations operations Investor Presentation August 2015 4
Wockhardt Today UK Ireland 9 sites 12 Chicago in India Baddi Manufacturing Locations globally Ankleshwar Daman (2 Plants) Aurangabad (5 Plants) Formulations APIs Investor Presentation August 2015 5
Wockhardt Today 3 R&D Centers worldwide USA / UK & India Investor Presentation August 2015 6
Key Business Update
Key Business Update Regulatory Update US FDA has completed inspection in one of the manufacturing facility in Himachal Pradesh in July, 2015 and no 483 has been issued to the company. US FDA’s inspection of Waluj facility completed during the quarter with minor observations. The Company’s on going efforts towards compliance measures for Chikalthana and Waluj facilities continues to be in place. Resumed Supplies to UK from our Chikalthana Facility. Research Update Received the coveted Breakthrough discovery (QIDP) status for another NCE product WCK 4873 during the quarter. Previously 2 of its drug WCK 771 and WCK 2349 received QIDP status. QIDP status allows for fast track review by US FDA and also grants a five year extensions to the drug patents in USA. Wockhardt is the only Indian company to receive QIDP status for its NCE products. Got approval from US FDA for marketing 5mg/5ml of Oxycodone HCL liquid from MGP. Oxycodone is used extensively in management of pain, especially in opioid tolerant patients. Filed for 54 patents during the quarter taking the cumulative filings to 2322 and has been granted 26 patents during the quarter taking the cumulative patents granted to 367. Investor Presentation August 2015 8
Q1FY16 Results
Sales – Growth of 15% over Q1FY15 Rs.crore Growth of 15% in Q1FY16 over Q1FY15 Investor Presentation August 2015 10
EBITDA – Growth of 165% over Q1FY15 Rs.crore Growth of 165% in Q1FY16 over Q1FY15 Investor Presentation August 2015 11
PAT – Growth of 470% over Q1FY15 Rs.crore Growth of 470% in Q1FY16 over Q1FY15 Investor Presentation August 2015 12
Research – 13.3% of Sales in Q1FY16 Growth of 31% in Q1FY16 over Q1FY15 Investor Presentation August 2015 13
US Business • Contributes 20% of Total Revenue. • Declines by 21% (26% in $ terms) 400 USA over Q1FY15. $48 • During the Q1FY16, 5 ANDA’s filed $36 200 & 1 approval received cumulative Rs.cr. ANDA’s pending for approval is 73. 287 227 - Q1-FY15 Q1-FY16 Investor Presentation August 2015 14
EU Operations UK Operations UK 420 • £ 37 1 New filing done and 1 New product launched in 370 Q1FY16. 320 • Rs.cr. UK operation Grows by 55% (grows by 59% £ terms) in 270 £ 23 Q1FY16. 220 170 237 368 120 Q1-FY15 Q1-FY16 Ireland € 5 44 43 Ireland Operations 42 • 41 Ireland Declines by 11% (growth of 4% in € terms) in Rs.cr. 40 € 6 Q1FY16. 39 38 37 44 39 36 Q1-FY15 Q1-FY16 Investor Presentation August 2015 15
India & Emerging Markets • India Business Grows by 27% for Q1FY16. • 24 new products in Q1FY16 launched in India. • Emerging Market operations grew by 47% in Q1FY16. India & Emerging Markets (EM) 500 97 400 EM 66 300 EM Rs.cr. 375 200 295 India India 100 0 Q1FY15 Q1FY16 Investor Presentation August 2015 16
For investor updates and communication please visit www.wockhardt.com For Information please contact Arun Khatanhar Tel.: +91 22 71596228 Akhatanhar@wockhardt.com 17 Investor Presentation August 2015
Recommend
More recommend
